Newsletter Tool

Today's Rundown

Merck's C-suite shakeup logs another loss as marketing exec Garay leaves for Moderna
BridgeBio strategy head departs amid company’s second round of layoffs this year
Boston Scientific surges 10% in Q1 amid slew of FDA nods, company reorganization
Walmart heir's nonprofit teams with Washington Regional to build new medical system in northwest Arkansas
Future shaky at Solid Bio as it shaves off 35% of workforce, chief operating officer plans exit
Pfizer and Biohaven clinch migraine approval in Europe, beating AbbVie to key market
Still looking to trim the fat, Acutus sells line of heart devices to Medtronic for $50M upfront
Former OptumRx CEO launches drug pricing startup with GV-led $35M round
GlaxoSmithKline's sales soar thanks to Shingrix, COVID-19 antibody but oncology lags
Abbott launches diabetes team-up with Ypsomed, CamDiab to bring artificial pancreas system to Europe
UPDATE: Amgen opts to DARP-out after seeing early data from $550M Molecular Partners biobucks collab
Broussard: Humana making headway in updating approach to MA sales after underwhelming open enrollment
Sensyne’s new CEO kicks off restructuring with potential mass layoffs, sale of several divisions

Featured Story

Merck's C-suite shakeup logs another loss as marketing exec Garay leaves for Moderna

By Fraiser Kansteiner

On May 31, Arpa Garay will enter the Moderna fold as chief commercial officer, the company said Wednesday. She's leaving just two months after nabbing a promotion at Merck & Co.

BridgeBio strategy head departs amid company’s second round of layoffs this year

By Max Bayer

BridgeBio is cutting staff for the second time this year as the company continues to reel from a phase 3 defeat in December. At the same time, the company's chief strategy officer is headed for the exit.

Boston Scientific surges 10% in Q1 amid slew of FDA nods, company reorganization

By Andrea Park

Boston Scientific may have slimmed down its sprawling corporate structure in the first quarter of the year, but that didn’t keep it from plumping up its earnings for the period.

Walmart heir's nonprofit teams with Washington Regional to build new medical system in northwest Arkansas

By Anastassia Gliadkovskaya

The goal is to expand access to specialty care and train a new generation of health professionals beyond general medicine.

Future shaky at Solid Bio as it shaves off 35% of workforce, chief operating officer plans exit

By Gabrielle Masson

Things are anything but stable at Solid Biosciences, a life sciences company targeting therapies for Duchenne muscular dystrophy, as it plans to cut over a third of its workforce—for the second time in two years—and Chief Operating Officer Joel Schneider, Ph.D., departs.

Pfizer and Biohaven clinch migraine approval in Europe, beating AbbVie to key market

By Fraiser Kansteiner

Looking to reach patients with a wide range of migraine symptoms in Europe, Pfizer and Biohaven are first on the scene with an oral CGRP drug approval.

Still looking to trim the fat, Acutus sells line of heart devices to Medtronic for $50M upfront

By Andrea Park

If there’s a name for the much less exciting inverse of a shopping spree, Acutus Medical is on it.

Former OptumRx CEO launches drug pricing startup with GV-led $35M round

By Rebecca Torrence

Former OptumRx CEO Mark Thierer is launching drug pricing startup Waltz Health with $35 million in funding led by GV (Google Ventures).

GlaxoSmithKline's sales soar thanks to Shingrix, COVID-19 antibody but oncology lags

By Angus Liu

Ever since the pandemic started holding back GlaxoSmithKline’s Shingrix, the company has repeatedly said its flagship shingles vaccine will return to growth. Now, the British pharma giant has gotten a taste of what that rebound will look like—even though CEO Emma Walmsley still warns of speed bumps ahead.

PM Tracker

Featured Story

Merck's C-suite shakeup logs another loss as marketing exec Garay leaves for Moderna

Top Stories

BridgeBio strategy head departs amid company’s second round of layoffs this year

Boston Scientific surges 10% in Q1 amid slew of FDA nods, company reorganization

Walmart heir's nonprofit teams with Washington Regional to build new medical system in northwest Arkansas

Future shaky at Solid Bio as it shaves off 35% of workforce, chief operating officer plans exit

Pfizer and Biohaven clinch migraine approval in Europe, beating AbbVie to key market

Still looking to trim the fat, Acutus sells line of heart devices to Medtronic for $50M upfront

Former OptumRx CEO launches drug pricing startup with GV-led $35M round

GlaxoSmithKline's sales soar thanks to Shingrix, COVID-19 antibody but oncology lags

Abbott launches diabetes team-up with Ypsomed, CamDiab to bring artificial pancreas system to Europe

UPDATE: Amgen opts to DARP-out after seeing early data from $550M Molecular Partners biobucks collab

Broussard: Humana making headway in updating approach to MA sales after underwhelming open enrollment

Sensyne’s new CEO kicks off restructuring with potential mass layoffs, sale of several divisions